In contrast, simultaneous use of HER2 targeting drugs and AIs has been challenged in a few pivotal trials that have already changed the standard care for ER+/HER2+ stage IV breast cancer patients (Riemsma et al, 2012). This evidence concerns the gene ERBB2 and breast cancer.